| Security Type | Security Class Title(1) | Fee Calculation Rule(2) | Amount Registered(3) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee |
| Equity | Common stock, par value $0.001 per share | Rule 457(a) | 3,829,780 | $17.05 | $65,297,749 | $147.60 per $1,000,000 | $9,637.95 |
| Total Offering Amounts | $65,297,749 | $9,637.95 | |||||
| Total Fee Offsets | — | ||||||
| Net Fee Due | $9,637.95 | ||||||
| (1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 shall also cover such indeterminate number of additional shares of common stock, par value $0.001 per share (the “Common Stock”) of Gyre Therapeutics, Inc. as may become issuable to prevent dilution in the event of stock splits, stock dividends or similar transactions pursuant to the terms of the Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan (the “Plan”). |
| (2) | Calculated solely for the purpose of determining the registration fee pursuant to Rules 457(c) and (h) of the Securities Act, and based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Capital Market on March 25, 2024. |
| (3) | Represents 3,829,780 shares of Common Stock reserved for issuance under the Plan. |
